Company Quick10K Filing
Quick10K
Eyenovia
Closing Price ($) Shares Out (MM) Market Cap ($MM)
$3.15 12 $38
10-Q 2019-06-30 Quarter: 2019-06-30
10-Q 2019-03-31 Quarter: 2019-03-31
10-K 2018-12-31 Annual: 2018-12-31
10-Q 2018-09-30 Quarter: 2018-09-30
10-Q 2018-06-30 Quarter: 2018-06-30
10-Q 2018-03-31 Quarter: 2018-03-31
10-K 2017-12-31 Annual: 2017-12-31
8-K 2019-08-12 Earnings, Exhibits
8-K 2019-07-11 Enter Agreement, Other Events, Exhibits
8-K 2019-06-25 Officers
8-K 2019-06-11 Officers, Shareholder Vote, Exhibits
8-K 2019-06-04 Other Events, Exhibits
8-K 2019-05-14 Earnings, Exhibits
8-K 2019-03-27 Earnings, Exhibits
8-K 2019-02-27 Regulation FD, Exhibits
8-K 2019-02-25 Other Events, Exhibits
8-K 2019-02-13 Officers, Exhibits
8-K 2019-02-13 Other Events, Exhibits
8-K 2019-02-06 Other Events, Exhibits
8-K 2019-01-30 Other Events, Exhibits
8-K 2018-12-19 Enter Agreement, Other Events, Exhibits
8-K 2018-12-03 Other Events, Exhibits
8-K 2018-11-26 Other Events, Exhibits
8-K 2018-11-13 Earnings, Other Events, Exhibits
8-K 2018-08-14 Earnings, Exhibits
8-K 2018-08-13 Regulation FD, Exhibits
8-K 2018-06-11 Officers, Amend Bylaw, Shareholder Vote, Exhibits
8-K 2018-03-26 Officers, Other Events, Exhibits
8-K 2018-03-06 Amend Bylaw, Exhibits
8-K 2018-01-24 Amend Bylaw, Other Events, Exhibits
ALNY Alnylam Pharmaceuticals 8,758
INVA Innoviva 1,111
AXSM Axsome Therapeutics 828
CYTK Cytokinetics 821
AMAG Amag Pharmaceuticals 362
MNKD Mannkind 201
CERC Cerecor 143
ATNM Actinium Pharmaceuticals 41
SPHS Sophiris Bio 24
RNN Rexahn Pharmaceuticals 6
EYEN 2019-06-30
Part I - Financial Information
Item 1. Financial Statements.
Note 1 - Business Organization, Nature of Operations and Basis of Presentation
Note 2 - Summary of Significant Accounting Policies
Note 3 - Prepaid Expenses and Other Current Assets
Note 4 - Accrued Compensation
Note 5 - Accrued Expenses and Other Current Liabilities
Note 6 - Commitments and Contingencies
Note 7 - Related Party Transactions
Note 8 - Stockholders' Equity
Note 9 - Employee Benefit Plans
Note 10 - Subsequent Events
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations.
Item 3. Quantitative and Qualitative Disclosures About Market Risk.
Item 4. Controls and Procedures.
Part II - Other Information
Item 1. Legal Proceedings.
Item 1A. Risk Factors.
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.
Item 3. Defaults Upon Senior Securities.
Item 4. Mine Safety Disclosures.
Item 5. Other Information.
Item 6. Exhibits.
EX-31.1 tv526622_ex31-1.htm
EX-31.2 tv526622_ex31-2.htm
EX-32.1 tv526622_ex32-1.htm
EX-32.2 tv526622_ex32-2.htm

Eyenovia Earnings 2019-06-30

EYEN 10Q Quarterly Report

Balance SheetIncome StatementCash Flow

10-Q 1 tv526622_10q.htm FORM 10-Q

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549

 

 

 

FORM 10-Q

 

 

 

  x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended: June 30, 2019

 

OR

 

  ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from _________________ to ______________________

 

COMMISSION FILE NUMBER: 001-38365

 

 

 

EYENOVIA, INC.
(Exact name of Registrant as Specified in Its Charter)

 

 

 

DELAWARE   47-1178401
(State or Other Jurisdiction of
Incorporation or Organization)
  (I.R.S. Employer
Identification No.)
     
295 Madison Avenue, Suite 2400
NEW YORK, NY
 

 

10017

(Address of Principal Executive Offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (917) 289-1117

 

 

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, $0.0001 Par Value   EYEN   Nasdaq Capital Market

 

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No ¨

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes x No ¨

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one):

 

Large accelerated filer ¨ Accelerated filer ¨
   
Non-accelerated filer x Smaller reporting company x
   
  Emerging growth company x

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any news or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes ¨ No x

 

The number of outstanding shares of the registrant’s common stock was 17,100,726 as of August 8, 2019.

 

 

 

 

 

EYENOVIA, INC.

 

FORM 10-Q

 

FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2019

 

TABLE OF CONTENTS

 

PART I - FINANCIAL INFORMATION  
   
Item 1. Financial Statements. 2
   
Condensed Balance Sheets as of June 30, 2019 (Unaudited) and December 31, 2018 2
   
Unaudited Condensed Statements of Operations for the Three and Six Months Ended June 30, 2019 and 2018 3
   
Unaudited Condensed Statements of Changes in Stockholders' Equity for the Six Months Ended June 30, 2019 and 2018 4
   
Unaudited Condensed Statements of Cash Flows for the Six Months Ended June 30, 2019 and 2018 5
   
Notes to Unaudited Condensed Financial Statements 6
   
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations. 14
   
Item 3. Quantitative and Qualitative Disclosures About Market Risk. 18
   
Item 4. Controls and Procedures. 18
   
PART II - OTHER INFORMATION  
   
Item 1. Legal Proceedings. 19
   
Item 1A. Risk Factors. 19
   
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds. 19
   
Item 3. Defaults Upon Senior Securities. 19
   
Item 4. Mine Safety Disclosures. 19
   
Item 5. Other Information. 19
   
Item 6. Exhibits. 20
   
SIGNATURES 21

 

1

 

 

PART I – FINANCIAL INFORMATION

 

Item 1. Financial Statements.

 

EYENOVIA, INC.

 

Condensed Balance Sheets

 

   June 30,   December 31, 
   2019   2018 
   (unaudited)     
         
Assets          
           
Current Assets:          
Cash and cash equivalents  $9,239,609   $19,728,200 
Prepaid expenses and other current assets   569,561    132,756 
           
Total Current Assets   9,809,170    19,860,956 
           
Property and equipment, net   31,632    36,738 
Deferred offering costs   77,376    - 
Security deposit   117,800    117,800 
           
Total Assets  $10,035,978   $20,015,494 
           
Liabilities and Stockholders' Equity          
           
Current Liabilities:          
Accounts payable  $1,802,386   $1,509,524 
Accrued compensation   437,700    912,104 
Accrued expenses and other current liabilities   133,146    677,213 
           
Total Current Liabilities   2,373,232    3,098,841 
           
Deferred rent   44,817    41,584 
           
Total Liabilities   2,418,049    3,140,425 
           
Commitments and contingencies (Note 6)          
           
Stockholders' Equity:          
Preferred stock, $0.0001 par value, 6,000,000 shares authorized; 0 shares issued and outstanding as of June 30, 2019 and as of December 31, 2018   -    - 
Common stock, $0.0001 par value, 90,000,000 shares authorized; 12,053,963 and 11,468,996 shares issued and outstanding as of June 30, 2019 and December 31, 2018, respectively   1,205    1,147 
Additional paid-in capital   55,396,914    53,388,216 
Accumulated deficit   (47,780,190)   (36,514,294)
           
Total Stockholders' Equity   7,617,929    16,875,069 
           
Total Liabilities and Stockholders' Equity  $10,035,978   $20,015,494 

 

The accompanying notes are an integral part of these condensed financial statements.

 

2

 

 

EYENOVIA, INC.

 

Condensed Statements of Operations

(unaudited)

 

   For the Three Months Ended   For the Six Months Ended 
   June 30,   June 30, 
   2019   2018   2019   2018 
                 
Operating Expenses:                    
Research and development  $3,568,022   $2,412,164   $7,576,918   $4,506,259 
General and administrative   1,809,106    908,806    3,751,869    2,246,455 
                     
Total Operating Expenses   5,377,128    3,320,970    11,328,787    6,752,714 
                     
Loss From Operations   (5,377,128)   (3,320,970)   (11,328,787)   (6,752,714)
                     
Other Income:                    
Interest income   43,616    1,907    62,891    4,044 
                     
Net Loss  $(5,333,512)  $(3,319,063)  $(11,265,896)  $(6,748,670)
                     
Net Loss Per Share                    
- Basic and Diluted  $(0.44)  $(0.33)  $(0.94)  $(0.77)
                     
Weighted Average Number of Common Shares Outstanding                    
- Basic and Diluted   12,034,450    9,998,646    11,975,035    8,807,864 

 

The accompanying notes are an integral part of these condensed financial statements.

 

3

 

 

EYENOVIA, INC.

 

Condensed Statements of Changes in Stockholders’ Equity

(unaudited)

 

   For the Six Months Ended June 30, 2019 
           Additional       Total 
   Common Stock   Paid-In   Accumulated   Stockholders' 
   Shares   Amount   Capital   Deficit   Equity 
                     
Balance - January 1, 2019   11,468,996   $1,147   $53,388,216   $(36,514,294)  $16,875,069 
                          
Exercise of stock options on a cashless basis   236,466    24    (24)   -    - 
                          
Exercise of stock options   313,686    31    483,857    -    483,888 
                          
Stock-based compensation   -    -    1,032,960    -    1,032,960 
                          
Net loss   -    -    -    (5,932,384)   (5,932,384)
                          
Balance - March 31, 2019   12,019,148    1,202    54,905,009    (42,446,678)   12,459,533 
                          
Exercise of stock options   34,815    3    67,886    -    67,889 
                          
Stock-based compensation   -    -    424,019    -    424,019 
                          
Net loss   -    -    -    (5,333,512)   (5,333,512)
                          
Balance - June 30, 2019   12,053,963   $1,205   $55,396,914   $(47,780,190)  $7,617,929 

 

 

   For the Six Months Ended June 30, 2018 
   Convertible Preferred Stock           Additional       Total 
   Series A   Series A-2   Series B   Common Stock   Paid-In   Accumulated   Stockholders' 
   Shares   Amount   Shares   Amount   Shares   Amount   Shares   Amount   Capital   Deficit   Equity 
                                             
Balance - January 1, 2018   2,932,431   $293    788,827   $79    918,983   $92    2,566,530   $257   $24,351,138   $(19,261,186)  $5,090,673 
                                                        
Conversion of convertible preferred stock into common stock upon completion of initial public offering   (2,932,431)   (293)   (788,827)   (79)   (918,983)   (92)   4,640,241    464         -    - 
                                                        
Issuance of common stock in initial public offering [1]   -    -    -    -    -    -    2,730,000    273    24,547,530    -    24,547,803 
                                                        
Stock-based compensation   -    -    -    -    -    -    -    -    650,576    -    650,576 
                        -                             - 
Net loss   -    -    -    -    -    -    -    -    -    (3,429,607)   (3,429,607)
                                                        
Balance - March 31, 2018   -    -    -    -    -    -    9,936,771    994    49,549,244    (22,690,793)   26,859,445 
                                                        
Conversion of convertible preferred stock into common stock upon completion of initial public offering   -    -    -    -    -    -    61,875    6    (6)   -    - 
                                                        
Stock-based compensation   -    -    -    -    -    -    -    -    1,512    -    1,512 
                                                        
Net loss   -    -    -    -    -    -    -    -    -    (3,319,063)   (3,319,063)
                                                        
Balance - June 30, 2018   -   $-    -   $-    -   $-    9,998,646   $1,000   $49,550,750   $(26,009,856)  $23,541,894 

 

[1] Includes gross proceeds of $27,300,000, less total issuance costs of $2,752,197.

 

The accompanying notes are an integral part of these condensed financial statements.

 

4

 

 

EYENOVIA, INC.

 

Condensed Statements of Cash Flows

(unaudited)

  

   For the Six Months Ended 
   June 30, 
   2019   2018 
         
Cash Flows From Operating Activities:          
Net loss  $(11,265,896)  $(6,748,670)
Adjustments to reconcile net loss to net cash used in operating activities:          
Depreciation and amortization   5,106    11,483 
Stock-based compensation   1,456,979    652,088 
Changes in operating assets and liabilities:          
Prepaid expenses and other current assets   (436,805)   (206,308)
Accounts payable   216,186    476,622 
Accrued compensation   (474,404)   - 
Accrued expenses and other current liabilities   (544,767)   383,482 
Deferred rent   3,233    - 
           
Net Cash Used In Operating Activities   (11,040,368)   (5,431,303)
           
Cash Flows From Financing Activities:          
Proceeds from exercise of stock options   551,777    - 
Proceeds from sale of common stock in initial public offering [1]   -    25,089,000 
Payment of initial public offering issuance costs   -    (345,497)
           
Net Cash Provided By Financing Activities   551,777    24,743,503 
           
Net (Decrease) Increase in Cash and Cash Equivalents   (10,488,591)   19,312,200 
           
Cash and Cash Equivalents - Beginning of Period   19,728,200    5,249,511 
           
Cash and Cash Equivalents - End of Period  $9,239,609   $24,561,711 
           
[1] Includes gross proceeds of $27,300,000, less issuance costs of $2,211,000 deducted directly from the offering proceeds. 
           
Supplemental Disclosure of Non-Cash Financing Activities:          
Exercise of stock options on a cashless basis  $24   $- 
Deferred offering costs included in accounts payable  $77,376   $- 
Conversion of convertible preferred stock into common stock  $-   $464 
Reversal of previously accrued initial public offering issuance costs  $-   $(133,000)
Reduction of additional paid-in capital for initial public offering issuance costs that were previously paid  $-   $(195,700)

 

The accompanying notes are an integral part of these condensed financial statements.

 

5

 

 

EYENOVIA, INC.

 

NOTES TO CONDENSED FINANCIAL STATEMENTS

 

(UNAUDITED)

 

Note 1 – Business Organization, Nature of Operations and Basis of Presentation

 

Eyenovia. Inc. (“Eyenovia” or the “Company”) is a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its patented piezo-print delivery technology, branded the OptejetTM. Eyenovia aims to achieve clinical microdosing of next-generation formulations of well-established ophthalmic pharmaceutical agents using its high-precision targeted ocular delivery system, which has the potential to replace conventional eye dropper delivery and improve safety, tolerability, patient compliance and topical delivery success for ophthalmic eye treatments. In the clinic, Optejet has demonstrated up to a 75% reduction in ocular drug and preservative exposure, with successful topical delivery that is consistent with the efficacy of traditional eyedrop administration. Using its proprietary delivery technology, Eyenovia is developing the next generation of smart ophthalmic therapies while targeting new indications for which there are currently no drug therapies approved by the U.S. Food and Drug Administration (the “FDA”). Eyenovia’s microdose therapeutics follow the FDA-designated pharmaceutical registration and regulatory process. Its products are not classified by the FDA as medical devices or drug-device combination products.

 

The accompanying unaudited condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all of the information and disclosures required by U.S. GAAP for complete financial statements. In the opinion of management, such statements include all adjustments (consisting only of normal recurring items) which are considered necessary for a fair presentation of the condensed financial statements of the Company as of June 30, 2019 and for the three and six months ended June 30, 2019 and 2018. The results of operations for the three and six months ended June 30, 2019 are not necessarily indicative of the operating results for the full year ending December 31, 2019 or any other period. These unaudited condensed financial statements should be read in conjunction with the audited financial statements and related disclosures of the Company as of December 31, 2018 and for the year then ended, which were filed with the Securities and Exchange Commission (“SEC”) on Form 10-K on March 27, 2019.

 

Note 2 – Summary of Significant Accounting Policies

 

Since the date of the Annual Report, there have been no material changes to the Company’s significant accounting policies, except as disclosed below.

 

Liquidity and Financial Condition

 

The Company has not yet generated revenues or achieved profitability and expects to continue to incur cash outflows from operations. The Company expects that its research and development and general and administrative expenses will continue to increase and, as a result, it will eventually need to generate significant product revenues to achieve profitability. Subsequent to June 30, 2019, the Company closed on a public offering of its common stock that provided approximately $13.0 million of net proceeds. See Note 10 – Subsequent Events for additional details.

 

The Company believes its current cash on hand, including the proceeds received from its subsequent public offering, is sufficient to meet its operating and capital requirements for at least the next twelve months from the date these financial statements are issued. Thereafter, the Company may need to raise further capital, through the sale of additional equity or debt securities, to support its future operations. The Company’s operating needs include the planned costs to operate its business, including amounts required to fund working capital and capital expenditures. The Company’s future capital requirements and the adequacy of its available funds will depend on many factors, including the Company’s ability to successfully commercialize its products and services, competing technological and market developments, and the need to enter into collaborations with other companies or acquire other companies or technologies to enhance or complement its product and service offerings. If the Company is unable to secure additional capital, it may be required to curtail its research and development initiatives and take additional measures to reduce costs in order to conserve its cash.

 

6

 

 

EYENOVIA, INC.

 

NOTES TO CONDENSED FINANCIAL STATEMENTS

 

(UNAUDITED)

 

Note 2 – Summary of Significant Accounting Policies – Continued

 

Cash and Cash Equivalents

 

The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents in the financial statements.

 

The Company has cash deposits in several financial institutions which, at times, may be in excess of Federal Deposit Insurance Corporation (“FDIC”) insurance limits. The Company has not experienced losses in such accounts and periodically evaluates the creditworthiness of its financial institutions. As of June 30, 2019 and December 31, 2018, the Company had cash and cash equivalent balances in excess of FDIC insurance limits of $8,989,609 and $19,478,200, respectively.

 

Deferred Offering Costs

 

Deferred offering costs, which primarily consist of direct, incremental professional fees incurred in connection with the Company’s public or private offerings are capitalized as non-current assets on the balance sheet. Upon the closing of an offering, the deferred offering costs are offset against the offering proceeds. As of June 30, 2019 and December 31, 2018, there were deferred offering costs for legal fees associated with the public offering of the Company’s common stock subsequent to June 30, 2019 in the amount of $77,376 and $0, respectively.

 

Stock-Based Compensation

 

The Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award. The fair value of the award is measured on the grant date and the fair value amount is then recognized over the period during which services are required to be provided in exchange for the award, usually the vesting period. Upon the exercise of an option, the Company issues new shares of common stock out of the shares reserved for issuance under its equity plans.

 

Net Loss Per Common Share

 

Basic net loss per common share is computed by dividing net loss by the weighted average number of common shares outstanding during the period. Diluted earnings per share reflects the potential dilution that could occur if securities or other instruments to issue common stock were exercised or converted into common stock.

 

The following securities are excluded from the calculation of weighted average diluted common shares because their inclusion would have been anti-dilutive:

 

   June 30, 
   2019   2018 
Options   1,563,366    1,860,084 
Warrants   -    61,875 
Restricted Stock Units   20,165    - 
Total potentially dilutive shares   1,583,531    1,921,959 

 

7

 

 

EYENOVIA, INC.

 

NOTES TO CONDENSED FINANCIAL STATEMENTS

 

(UNAUDITED)

 

Note 2 – Summary of Significant Accounting Policies – Continued

 

Recently Adopted Accounting Pronouncements

 

 In August 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2016-15, “Statement of Cash Flows (Topic 230) Classification of Certain Cash Receipts and Cash Payments” (“ASU 2016-15”). The new standard will make eight targeted changes to how cash receipts and cash payments are presented and classified in the statement of cash flows. The new standard is effective for fiscal years beginning after December 15, 2018. The new standard requires adoption on a retrospective basis unless it is impracticable to apply, in which case the Company would be required to apply the amendments prospectively as of the earliest date practicable. This standard was adopted on January 1, 2019 and did not have a material impact on the Company’s financial position, results of operations or cash flows.

 

 In June 2018, the FASB issued ASU No. 2018-07, “Compensation — Stock Compensation (Topic 718)” (“ASU 2018-07”). ASU 2018-07 is intended to reduce cost and complexity of financial reporting for non-employee share-based payments. Currently, the accounting requirements for non-employee and employee share-based payments are significantly different. ASU 2018-07 expands the scope of Topic 718, which currently only includes share-based payments to employees, to include share-based payments to non-employees for goods or services. Consequently, the accounting for share-based payments to non-employees and employees will be substantially aligned. This ASU supersedes Subtopic 505-50, “Equity — Equity-Based Payments to Nonemployees.” The amendments to ASU 2018 - 07 are effective for fiscal years beginning after December 15, 2019, and interim periods within fiscal years beginning after December 15, 2020. Early adoption is permitted, but no earlier than a company’s adoption date of ASU No. 2014-09, (Topic 606), “Revenue from Contracts with Customers.” This standard was adopted on January 1, 2019 and did not have a material impact on the Company’s financial position, results of operations or cash flows.

 

Note 3 – Prepaid Expenses and Other Current Assets

 

As of June 30, 2019 and December 31, 2018, prepaid expenses and other current assets consisted of the following:

 

   June 30,   December 31, 
   2019   2018 
   (unaudited)     
Prepaid insurance expenses  $274,685   $39,465 
Payroll tax credit receivable   101,049    - 
Prepaid research & development expenses   84,058    - 
Prepaid rent and security deposit   30,837    75,729 
Prepaid patent expenses   27,832    10,562 
Prepaid filing expenses   27,500    - 
Prepaid conference expenses   23,600    7,000 
Total prepaid expenses and other current assets  $569,561   $132,756 

 

Note 4 – Accrued Compensation

 

As of June 30, 2019 and December 31, 2018, accrued compensation consisted of the following:

 

   June 30,   December 31, 
   2019   2018 
   (unaudited)     
Accrued bonus expenses  $332,771   $694,490 
Accrued payroll expenses   104,929    217,614 
Total accrued compensation  $437,700   $912,104 

 

8

 

 

EYENOVIA, INC.

 

NOTES TO CONDENSED FINANCIAL STATEMENTS

 

(UNAUDITED)

 

Note 5 – Accrued Expenses and Other Current Liabilities

 

As of June 30, 2019 and December 31, 2018, accrued expenses and other current liabilities consisted of the following:

 

   June 30,   December 31, 
   2019   2018 
   (unaudited)     
Accrued research and development expenses  $46,927   $375,204 
Credit card payable   29,885    9,466 
Accrued professional services   26,747    111,728 
Accrued travel and enterntainment expenses   14,388    - 
Accrued franchise tax   12,875      
Accrued legal expenses   -    168,650 
Other   2,324    12,165 
Total accrued expenses and other current liabilities  $133,146   $677,213 

 

Note 6 – Commitments and Contingencies

 

Employment Agreements

 

Effective February 15, 2019, the Company entered into at-will executive employment agreements with Tsontcho Ianchulev, its Chief Executive Officer and Chief Medical Officer, John Gandolfo, its Chief Financial Officer, Jennifer Clasby, its Vice President, Clinical Operations, Luke Clauson, its Vice President, Research and Development and Manufacturing, and Michael Rowe, its Vice President, Marketing.

 

Each of the employment agreements provides that if the executive’s employment is terminated by the Company without “Cause” or the executive suffers an “Involuntarily Termination” (each as defined in the employment agreements), provided that the executive has signed a full release of all claims, the executive will be entitled to receive: (i) severance pay equal to three months of his or her then-current base salary (currently estimated at approximately $419,000 in the aggregate), and (ii) a reimbursement for health insurance benefits under COBRA for the executive and his or her spouse and dependents for a period of three months or until the executive becomes eligible for comparable insurance benefits from another employer, whichever is earlier.

 

Each of the employment agreements also provides that if within 12 months following any “Corporate Transaction” (as defined in the employment agreements) of the Company, if the executive’s employment is terminated by the Company without Cause or the executive suffers an Involuntary Termination, provided that the executive has signed a full release of all claims, the executive will be entitled to receive, in lieu of what is described in the above paragraph: (i) severance pay equal to 12 months of his or her then-current base salary (currently estimated at approximately $1,677,000 in the aggregate), and (ii) a reimbursement for health insurance benefits under COBRA for the executive and his or her spouse and dependents for a period of 12 months or until the executive becomes eligible for comparable insurance benefits from another employer, whichever is earlier.

 

Litigations, Claims and Assessments

 

In the normal course of business, the Company may be involved in legal proceedings, claims and assessments arising in the ordinary course of business. The Company records legal costs associated with loss contingencies as incurred and accrues for all probable and estimable settlements.

 

9

 

 

EYENOVIA, INC.

 

NOTES TO CONDENSED FINANCIAL STATEMENTS

 

(UNAUDITED)

 

Note 7 – Related Party Transactions

 

Consulting Agreements

 

A company in which a member of the Company’s Board of Directors is part owner is a party to a consulting agreement with the Company dated July 6, 2017 that provides for the payment of $9,567 per month, and $250 per hour for any additional work, for advisory services performed by such director. The Company incurred expenses of $50,634 and $34,884 for the three months ended June 30, 2019 and 2018, respectively, and $98,835 and $92,460 for the six months ended June 30, 2019 and 2018, respectively, related to the agreement which was included within general and administrative expenses on the condensed statements of operations.

 

Lease Agreements

 

The Company paid $3,000 and $4,000 per month as of July 2016 and January 2018, respectively, to a company controlled by a member of its Board of Directors for office space in New York, NY for its Chief Executive Officer. The Company left the space on August 31, 2018. During the three months ended June 30, 2019 and 2018, the Company recorded rent expense of $0 and $9,000, respectively, and $0 and $18,000 for the six months ended June 30, 2019 and 2018, respectively, related to the office space which was included within general and administrative expenses on the condensed statements of operations.

 

The Company’s Vice President of Research and Development and Manufacturing (“VP of R&D”) owns a company that entered into a lease agreement with the Company on September 15, 2016 to lease 953 square feet of space located in Reno, NV with respect to its research and development activities. The initial monthly base rent was $3,895 per month over the term of the lease and the security deposit was $3,895. On September 15, 2018, the Company amended the lease agreement to extend it until September 14, 2020 and increase the monthly base rent and security deposit to $4,012. The Company made $40,000 of leasehold improvements related to this lease which are included on the balance sheet. The Company’s rent expense amounted to $12,036 and $11,685 for the three months ended June 30, 2019 and 2018, respectively, and $24,072 and $23,370, respectively, for the six months ended June 30, 2019 and 2018, respectively.

 

Research and Development Activities

 

The VP of R&D is the sole owner and President of a company that performs contract engineering services for the Company. During the three and six months ended June 30, 2019, the Company recognized research and development expense of $210,419 and $530,560, respectively, related to services provided by such vendor. During the three and six months ended June 30, 2018, the Company recognized research and development expense of $196,432 and $428,443, respectively, related to services provided by such vendor. The Company had a liability of $211,160 and $100,667 to the vendor as of June 30, 2019 and December 31, 2018, respectively.

 

The Company recognized $46,050 and $94,100 of compensation expense related to the VP of R&D’s salary during the three and six months ended June 30, 2019, respectively. The Company recognized $41,250 and $82,500 of compensation expense during the three and six months ended June 30, 2018, respectively.

 

License Agreement

 

During 2015, the Company entered into a license agreement with Senju Pharmaceuticals Co., Ltd. (“Senju”) whereby the Company agreed to grant to Senju an exclusive, royalty-bearing license for its microdose product candidates for Asia to sublicense, develop, make, have made, manufacture, use, import, market, sell, and otherwise distribute the microdose product candidates. In consideration for the license, Senju agreed to pay to Eyenovia five percent (5%) royalties for the term of the license agreement. The agreement will continue in full force and effect, on a country-by-country basis, until the latest to occur of: (i) the tenth (10th) anniversary of the first commercial sale of a microdose product candidate in Asia; or (ii) the expiration of the licensed patents. As of the date of this filing, there had been no commercial sales of a microdose product candidate in Asia, such that no royalties had been earned. Senju is owned by the family of a former member of the Company’s Board of Directors and both beneficially own greater than 5% of the Company’s common stock.

 

10

 

 

EYENOVIA, INC.

 

NOTES TO CONDENSED FINANCIAL STATEMENTS

 

(UNAUDITED)

 

Note 8 – Stockholders’ Equity

 

Stock Options

 

During the six months ended June 30, 2019, the Company granted ten-year stock options to purchase an aggregate of 11,000 shares of common stock to its employees under the 2018 Plan. The 11,000 shares vest over three years from the date of grant with one-third vesting on the one-year anniversary of the date of grant and the balance vesting monthly over the remaining 24 months, subject to continued service to the Company. The stock options have an exercise price of $2.74 per share, which represents the Company’s closing stock price on the date of grant. The stock options had a grant date value of $27,500, which the Company expects to recognize over the vesting period.

  

On January 2, 2019, stock options to purchase 180,000 and 133,686 shares of common stock with an exercise price of $1.24 and $1.95 per share, respectively, were exercised for aggregate proceeds of $483,888.

 

On February 6, 2019, stock options to purchase an aggregate of 320,001 shares of common stock with an exercise price of $1.24 per share were exercised on a cashless basis, which resulted in the issuance of an aggregate of 236,466 shares of common stock.

 

On February 13, 2019, the Board of Directors of the Company approved the acceleration and immediate vesting of 124,210 stock options originally granted to Dr. Ianchulev on July 24, 2018 in connection with his employment. In connection with the acceleration and immediate vesting, the Company recognized $609,322 of stock-based compensation expense during the six months ended June 30, 2019, which represents the remaining unamortized grant date fair value of the award.

 

On May 14, 2019, stock options to purchase 34,815 shares of common stock with an exercise price of $1.95 per share were exercised for aggregate proceeds of $67,889.

 

In applying the Black-Scholes option pricing model to stock options granted, the Company used the following approximate assumptions:

 

   For the Three Months Ended  For the Six Months Ended  
   June 30,  June 30,  
   2019  2018  2019    2018  
Expected term (years)  n/a  5.82 - 10.0  5.85    5.82 - 10.0  
Risk free interest rate  n/a  2.69% - 2.83%  2.53%   2.69% - 2.83%  
Expected volatility  n/a  140%  139%   140%  
Expected dividends  n/a  0.00%  0.00%   0.00%  

 

The Company has computed the fair value of stock options granted using the Black-Scholes option pricing model. Option forfeitures are accounted for at the time of occurrence. The expected term is the estimated period of time that options granted are expected to be outstanding. The Company utilizes the “simplified” method to develop an estimate of the expected term of “plain vanilla” employee option grants. The Company does not yet have a trading history to support its historical volatility calculations. Accordingly, the Company is utilizing an expected volatility figure based on a review of the historical volatility of comparable entities over a period of time equivalent to the expected life of the instrument being valued. The risk-free interest rate was determined from the implied yields from U.S. Treasury zero-coupon bonds with a remaining term consistent with the expected term of the instrument being valued.

 

There were no stock options granted during the three months ended June 30, 2019. The weighted average estimated grant date fair value of the stock options granted for the six months ended June 30, 2019 was approximately $2.74 per share. The weighted average estimated grant date fair value of the stock options granted for the three and six months ended June 30, 2018 was approximately $8.72 per share.

 

11

 

 

EYENOVIA, INC.

 

NOTES TO CONDENSED FINANCIAL STATEMENTS

 

(UNAUDITED)

 

Note 8 – Stockholders’ Equity – Continued

 

Stock Options – Continued

 

A summary of the option activity during the six months ended June 30, 2019 is presented below:

 

           Weighted     
       Weighted   Average     
       Average   Remaining   Aggregate 
   Number of   Exercise   Life   Intrinsic 
   Options   Price   In Years   Value 
Outstanding January 1, 2019   2,220,868   $3.01           
Granted   11,000    2.74           
Exercised   (668,502)   1.42           
Forfeited   -    -           
Outstanding June 30, 2019   1,563,366   $3.69    8.0   $2,459,670 
                     
Exercisable June 30, 2019   921,648   $3.07    7.6   $1,764,949 

 

The following table presents information related to stock options as of June 30, 2019:

  

Options Outstanding   Options Exercisable 
        Weighted     
    Outstanding   Average   Exercisable 
Exercise   Number of   Remaining Life   Number of 
Price   Options   In Years   Options 
$1.24    260,000    5.7    260,000 
$1.95    700,281    8.0    412,212 
$2.74    11,000    -    - 
$4.00    2,000    -    - 
$5.10    6,000    -    - 
$5.19    16,500    -    - 
$5.25    26,668    7.3    17,916 
$6.20    311,499    9.1    146,535 
$6.30    60,000    9.0    18,333 
$8.72    169,418    8.8    66,652 
      1,563,366    7.6    921,648 

 

12

 

 

EYENOVIA, INC.

 

NOTES TO CONDENSED FINANCIAL STATEMENTS

 

(UNAUDITED)

 

Note 8 – Stockholders’ Equity – Continued

 

Stock-Based Compensation Expense

 

The Company records stock-based compensation expense related to stock options and restricted stock units. During the three months ended June 30, 2019 and 2018, the Company recorded expense of $424,019 ($206,834 of which was included within research and development expenses and $217,185 was included within general and administrative expenses on the condensed statements of operations) and $1,512 ($11,369 of which was included within research and development expenses and $(9,857) was included within general and administrative expenses on the condensed statements of operations which includes a credit associated with the mark-to-market of non-employee options), respectively. During six three months ended June 30, 2019 and 2018, the Company recorded expense of $1,456,979 ($900,917 of which was included within research and development expenses and $556,062 was included within general and administrative expenses on the condensed statements of operations) and $652,088 ($316,290 of which was included within research and development expenses and $335,798 was included within general and administrative expenses on the condensed statements of operations), respectively. As of June 30, 2019, there was $2,301,431 of unrecognized stock-based compensation expense which will be recognized over a weighted average period of 1.7 years.

 

Note 9 – Employee Benefit Plans

 

401(k) Plan

 

In April 2019, the Company adopted the Eyenovia 401(k) Plan (the “Plan”), which went into effect in May 2019. All Company employees are able to participate in the Plan, subject to eligibility requirements as outlined in the Plan documents. Under the terms of the Plan, eligible employees are able to defer a percentage of their pay every pay period up to annual limitations set by Congress and the Internal Revenue Service under Section 401(k) of the Internal Revenue Code. For 2019, the Company’s Board of Directors has approved a matching contribution equal to 100% of elective deferrals up to 4% of eligible earnings with the matching contribution subject to certain vesting requirements as outlined in the Plan documents. During the three and six months ended June 30, 2019, the Company recorded expense of $16,043 associated with its matching contributions.

 

Note 10 – Subsequent Events

 

Public Offering

 

On July 15, 2019, the Company closed an underwritten public offering of 4,388,490 shares of its common stock at a public offering price of $2.78 per share. The Company granted the underwriters a 30-day over-allotment option to purchase up to an additional 658,273 shares of the Company’s common stock at the same price, which was exercised in full on July 16, 2019. Including the over-allotment shares, the Company issued a total of 5,046,763 shares in the underwritten public offering, and received gross proceeds of approximately $14.0 million and net proceeds of approximately $13.0 million, after deducting underwriting discounts, commissions and other offering expenses.

 

13

 

 

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

 

The following discussion and analysis of the results of operations and financial condition of Eyenovia, Inc. (“Eyenovia,” the “Company,” “we,” “us” and “our”) as of June 30, 2019 and for the three and six months ended June 30, 2019 and 2018 should be read in conjunction with our unaudited financial statements and the notes thereto included elsewhere in this Quarterly Report on Form 10-Q and with our audited financial statements and the notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2018 as filed with the Securities and Exchange Commission (“SEC”) on March 27, 2019.

 

Forward Looking Statements

 

This report contains “forward-looking statements.” Specifically, all statements other than statements of historical facts included in this report, including regarding our financial position, business strategy and plans and objectives of management for future operations, are forward-looking statements. These forward-looking statements are based on the beliefs of management at the time these statements were made, as well as assumptions made by and information currently available to management. When used in this report, the words “anticipate,” “believe,” “estimate,” “expect,” “may,” “might,” “will,” “continue” “intend,” and “plan” and words or phrases of similar import are intended to identify forward-looking statements. These statements reflect our current view with respect to future events and are subject to risks, uncertainties and assumptions related to various factors that could cause actual results and the timing of events to differ materially from future results expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed in the section titled “Risk Factors” included in our most recent Annual report on Form 10-K filed with the SEC. Furthermore, such forward-looking statements speak only as of this Quarterly Report on Form 10-Q. Except as required by law, we undertake no obligation to update any forward-looking statements to reflect events or circumstances after the date of such statements.

 

Overview

 

We are a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing our patented piezo-print delivery technology, branded the OptejetTM. Eyenovia aims to achieve clinical microdosing of next-generation formulations of well-established ophthalmic pharmaceutical agents using its high-precision targeted ocular delivery system, which has the potential to replace conventional eye dropper delivery and improve safety, tolerability, patient compliance and topical delivery success for ophthalmic eye treatments. In the clinic, Optejet has demonstrated up to a 75% reduction in ocular drug and preservative exposure, with successful topical delivery that is consistent with the efficacy of traditional eye drop administration. Using its proprietary delivery technology, Eyenovia is developing the next generation of smart ophthalmic therapies while targeting new indications for which there are currently no drug therapies approved by the United States Food and Drug Administration, or the FDA. Eyenovia’s microdose therapeutics follow the FDA-designated pharmaceutical registrational and regulatory process. Its products are not classified by the FDA as medical devices or drug-device combination products.

 

Eyenovia has completed its Phase III trials for MicroStat and announced positive results from these studies, known as MIST-1 and MIST-2. MicroStat is a fixed combination formulation of phenylephrine-tropicamide for mydriasis (pupil dilation), designed to be a novel approach for the estimated 80 million office-based comprehensive and diabetic eye exams performed every year in the United States. With the primary objectives of its Phase III program for MicroStat met, Eyenovia plans to submit a new drug application, or NDA, to the FDA in 2020 for marketing approval in the United States. In February 2019, the FDA accepted Eyenovia’s investigational new drug application, or IND, to initiate our Phase III registration trial of MicroPine (the CHAPERONE Study) to reduce the progression of myopia in children. We enrolled our first patient in the CHAPERONE study in June 2019. MicroPine is a first-in-class topical therapy for the treatment of progressive myopia, a back-of-the-eye ocular disease associated with pathologic axial elongation and sclero-retinal stretching affecting approximately five million people in the United States. We also have received clear feedback from the FDA regarding the requirements for Phase III trials for our MicroProst program. MicroProst is a novel latanoprost formulation for lowering intraocular pressure, or IOP, in patients with ocular hypertension, primary open angle glaucoma, and chronic angle closure glaucoma. MicroTears, our over-the-counter, or OTC, product candidate for hyperemia (red eye), pruritis (itch) and dry eye, will not require Phase III trials. We plan to launch MicroTears concurrently with our potential commercialization of MicroStat.

 

Results from our three Phase II clinical trials have been published in peer-reviewed literature. Two studies evaluating our mydriatic agents demonstrated how the Optejet consistently delivered precision dosing at the volume of the eye’s natural tear film capacity of 6-8 µL, which reduced ocular and systemic drug and preservative exposure, while demonstrating pupil dilation comparable to conventional eye drops with fewer side effects. In the third study, we evaluated usability, patient tolerability and IOP lowering of microdosed latanoprost administered with the Optejet. In this study, eyes receiving microdosed latanoprost achieved IOP reduction consistent with published literature on latanoprost eye drops, and administration of the medication was successful in a single attempt in more than 90% of cases. Based on the results from these clinical trials, we are able to advance MicroStat, MicroPine and MicroProst into Phase III utilizing the 505(b)(2) pathway and plan to do the same with MicroPine and MicroProst. Where possible, we also intend to use this pathway for future clinical trials in new indications with significant unmet needs.

 

14

 

 

We have not completed development of any product candidate and we have therefore not generated any revenues from product sales.

 

Historically, we have financed our operations principally through stock offerings, including our initial public offering and follow-on public offering that closed in January and December 2018, respectively and our public offering that closed in July 2019. Although it is difficult to predict our liquidity requirements, based upon our current operating plan, we believe we will have sufficient cash to meet our projected operating requirements for at least the next twelve months. Thereafter, the Company will need to raise further capital, through the sale of additional equity or debt securities, to support its future operations. If the Company is unable to secure additional capital, it may be required to curtail its research and development initiatives and take additional measures to reduce costs.

 

Our net losses were $5.3 million and $11.3 million for the three and six months ended June 30, 2019, respectively. As of June 30, 2019, we had working capital and an accumulated deficit of $7.4 million and $47.8 million, respectively.

 

Financial Overview

 

Revenue

 

We have not generated any revenue from product sales since our inception and do not expect to generate any revenue from the sale of products in the near future. Our ability to generate revenues will depend heavily on the successful development, regulatory approval and commercialization of our micro-therapeutic product candidates.

 

Research and Development Expenses

 

Research and development expenses are incurred in connection with the research and development of our micro-therapeutics and consist primarily of contract service expenses. Given where we are in our life cycle, we do not separately track research and development expenses by project. Our research and development expenses consist of:

 

  · direct clinical and non-clinical expenses, which include expenses incurred under agreements with contract research organizations, contract manufacturing organizations, and costs associated with preclinical activities, development activities and regulatory activities;

 

  · personnel-related expenses, which include expenses related to consulting agreements with individuals that have since entered into employment agreements with us as well as salaries and other compensation of employees that is attributable to research and development activities; and

 

  · facilities and other expenses, which include direct and allocated expenses for rent and maintenance of facilities, marketing, insurance and other supplies used in research and development activities.

 

We expense research and development costs as incurred. We record costs for some development activities, such as clinical trials, based on an evaluation of the progress to completion of specific tasks using data such as subject enrollment, clinical site activations or other information our vendors provide to us.

 

We expect that our research and development expenses will increase with the continuation of the aforementioned initiatives.

 

General and Administrative Expenses

 

General and administrative expenses consist primarily of payroll and related expenses, legal and other professional services, as well as non-cash stock-based compensation expense. We anticipate that our general and administrative expenses will increase in the future as we increase our headcount to support our continued research and development and the potential commercialization of our product candidates. We also anticipate increased expenses related to audit, legal, regulatory, and tax-related services associated with maintaining compliance with exchange listing and SEC requirements. In addition, director and officer insurance premiums and investor relations costs associated with being a public company are expected to increase in future periods.

 

15

 

 

Results of Operations

 

Three Months Ended June 30, 2019 Compared with Three Months Ended June 30, 2018

 

Research and Development Expenses

 

Research and development expenses for the three months ended June 30, 2019 totaled $3.6 million, an increase of $1.2 million, or 48%, as compared to $2.4 million recorded for the three months ended June 30, 2018. Research and development expenses consisted of the following:

 

   For the Three Months Ended 
   June 30, 
   2019   2018 
Direct clinical and non-clinical expenses  $2,219,648   $1,123,115 
Personnel-related expenses   783,708    629,776 
Non-cash stock-based compensation expenses   206,834    11,369 
Facilities and other expenses   357,832    647,904 
Total research and development expenses  $3,568,022   $2,412,164 

 

The increase in direct clinical and non-clinical expenses and personnel-related expenses is primarily due to an increase in contracted services and the hiring of three additional employees as we expanded our research and development activities for our micro-therapeutic products. The increase in non-cash stock-based compensation expense as compared to the 2018 period was due to stock options that were granted subsequent to June 30, 2018. The decrease in facilities and other expenses was due to a decrease in research and development related supplies and materials.

 

General and Administrative Expenses

 

General and administrative expense for the three months ended June 30, 2019 totaled $1.8 million, an increase of $0.9 million, or 99%, as compared to $0.9 million recorded for the three months ended June 30, 2018. This increase was primarily attributable to an increase in expenses related to payroll of $0.2 million from the hiring of an additional five employees, non-cash stock-based compensation of $0.2 million, advertising and marketing of $0.2 million related to marketing analysis upon potential commercialization, $0.2 million of costs related to being a public company and insurance expense of $0.1 million.

 

Six Months Ended June 30, 2019 Compared with Six Months Ended June 30, 2018

 

Research and Development Expenses

 

Research and development expenses for the six months ended June 30, 2019 totaled $7.6 million, an increase of $3.1 million, or 68%, as compared to $4.5 million recorded for the six months ended June 30, 2018. Research and development expenses consisted of the following:

 

   For the Six Months Ended 
   June 30, 
   2019   2018 
Direct clinical and non-clinical expenses  $4,409,969   $2,189,392 
Personnel-related expenses   1,524,941    1,050,992 
Non-cash stock-based compensation expenses   900,917    316,290 
Facilities and other expenses   741,091    949,585 
Total research and development expenses  $7,576,918   $4,506,259 

 

The increase in direct clinical and non-clinical expenses and personnel-related expenses is primarily due to an increase in contracted services and the hiring of three additional employees as we expanded our research and development activities for our micro-therapeutic products. The increase in non-cash stock-based compensation expense as compared to the 2018 period was primarily due to certain stock options that were accelerated and immediately vested in February 2019. The decrease in facilities and other expenses was due to a decrease in research and development related supplies and materials.

 

16

 

 

General and Administrative Expenses

 

General and administrative expense for the six months ended June 30, 2019 totaled $3.8 million, an increase of $1.6 million, or 67%, as compared to $2.2 million recorded for the six months ended June 30, 2018. This increase was primarily attributable to an increase in payroll related expenses of $0.5 million due to the hiring of an additional five employees, $0.4 million in costs related to being a public company, $0.25 million in advertising and marketing expenses related to marketing analysis upon potential commercialization, $0.2 million of non-cash stock-based compensation, and $0.1 million in rent expense related to the addition of our new leased office space in New York, NY in August 2018.

 

Liquidity and Capital Resources

 

Since inception, we have experienced negative cash flows from operations. At June 30, 2019, our accumulated deficit since inception was $47.8 million.

 

At June 30, 2019, we had working capital of $7.4 million and stockholders’ equity of $7.6 million. At June 30, 2019 and December 31, 2018, we had no debt outstanding.

 

At June 30, 2019, we had a cash balance of $9.2 million. In July 2019, we raised aggregate net proceeds of approximately $13 million in connection with our underwritten public offering. We expect our current cash on hand to be sufficient to meet our operating and capital requirements for at least the next twelve months from the date of this filing. Thereafter, we will likely need to raise further capital, through the sale of additional equity or debt securities, to support our future operations. Our operating needs include the planned costs to operate our business, including amounts required to fund research and development activities including clinical studies, working capital and capital expenditures. Our future capital requirements and the adequacy of our available funds will depend on many factors, including our ability to successfully commercialize our products and services, competing technological and market developments, and the need to enter into collaborations with other companies or acquire other companies or technologies to enhance or complement our product and service offerings. If we are unable to secure additional capital, we may be required to curtail our research and development initiatives and take additional measures to reduce costs in order to conserve our cash.

 

During the six months ended June 30, 2019 and 2018, our sources and uses of cash were as follows:

 

Net cash used in operating activities for the six months ended June 30, 2019 was $11.0 million, which includes cash used to fund a net loss of $11.3 million, reduced by $1.5 million of non-cash expenses, plus $1.2 million of cash used to fund changes in operating assets and liabilities. Net cash used in operating activities for the six months ended June 30, 2018 was $5.4 million, which includes cash used to fund a net loss of $6.7 million, partially offset by $0.7 million of non-cash expenses, partially offset by $0.7 million of cash provided by changes in operating assets and liabilities.

 

Cash provided by financing activities for the six months ended June 30, 2019 totaled $0.6 million, which was attributable to proceeds from the exercise of stock options. Cash provided by financing activities for the six months ended June 30, 2018 totaled $24.7 million, which was primarily attributable to $25.1 million of proceeds from the sale of common stock in our initial public offering, reduced by issuance costs related to our initial public offering of $0.3 million.

 

Off-Balance Sheet Arrangements

 

There are no off-balance sheet arrangements between us and any other entity that have, or are reasonably likely to have, a current or future effect on financial conditions, changes in financial conditions, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that is material to stockholders.

 

Critical Accounting Policies

 

For a description of our critical accounting policies, see Note 2 – Summary of Significant Accounting Policies in Part 1, Item 1 of this Quarterly Report on Form 10-Q.

 

Recently Adopted Accounting Pronouncements

 

For a description of recently adopted accounting pronouncements, including adoption dates and estimated effects, if any, on our consolidated financial statements, see Note 2 – Summary of Significant Accounting Policies in Part 1, Item 1 of this Quarterly Report on Form 10-Q.

 

17

 

 

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

 

Smaller reporting companies such as us are not required to provide the information required by this item.

 

Item 4. Controls and Procedures.

 

Evaluation of Disclosure Controls and Procedures

 

As of the end of the period covered by this Quarterly Report on Form 10-Q, we carried out an evaluation, under the supervision and with the participation of our management, including our principal executive officer and principal financial and accounting officer, of the effectiveness of the design and operation of our disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”).

 

In designing and evaluating our disclosure controls and procedures, management recognizes that any disclosure controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints and that management is required to apply its judgment in evaluating the benefits of possible controls and procedures relative to their costs.

 

Based on their evaluation, our principal executive officer and principal financial and accounting officer concluded that as of June 30, 2019 our disclosure controls and procedures were designed to, and were effective to, provide assurance at a reasonable level that the information we are required to disclose in reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms, and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial and accounting officer, as appropriate, to allow timely decisions regarding required disclosures as of June 30, 2019.

 

Changes in Internal Control over Financial Reporting

 

There has been no change in our internal control over financial reporting that occurred during the second quarter of 2019 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

 

18

 

 

PART II - OTHER INFORMATION

 

Item 1. Legal Proceedings.

 

None.

 

Item 1A. Risk Factors.

 

Smaller reporting companies such as us are not required to provide the information required by this item.

 

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

 

Recent Sales of Unregistered Securities

 

During the six-month period ended June 30, 2019, we issued an aggregate of 584,967 shares of our common stock upon the exercise of stock options previously granted under our 2014 Equity Incentive Plan, as amended, at a weighted-average exercise price of $1.42 per share, for aggregate consideration of $551,777 and 83,535 shares of common stock were forfeited to the Company upon the cashless exercise of certain options. The offer, sale and issuance of these securities were deemed to be exempt from registration either under the Securities Act, in reliance on Rule 701 promulgated under the Securities Act, as a transaction under compensatory benefit plans, or Section 4(a)(2) of the Securities Act, as a transaction not involving a public offering. Appropriate legends were affixed to the securities issued in these transactions.

 

Use of Proceeds from Registered Securities Offering

 

On January 24, 2018, the SEC declared effective our Registration Statement on Form S-1 (File No. 333-222162), as amended, filed in connection with the initial public offering of our common stock. Pursuant to the Registration Statement, we registered the offer and sale of up to $35,000,000 of our common stock. On January 29, 2018, we issued and sold 2,730,000 shares of our common stock at a price to the public of $10.00 per share. Ladenburg Thalmann & Co. Inc., a subsidiary of Ladenburg Thalmann Financial Services Inc., and Roth Capital Partners acted as joint book-running managers for the offering.

 

As a result of the offering, we received net proceeds of approximately $24.5 million in the aggregate, which consists of gross proceeds of $27.3 million, offset by underwriting discounts and commissions of approximately $1.9 million and other offering expenses of approximately $0.9 million. No payments for such expenses were made directly or indirectly to (i) any of our officers or directors or their associates, (ii) any persons owning 10% or more of any class of our equity securities or (iii) any of our affiliates. The offering has closed.

 

There has been no material change in the expected use of the net proceeds from our initial public offering as described in our final prospectus, dated January 24, 2018, filed with the SEC pursuant to Rule 424(b) relating to our Registration Statement on Form S-1.

 

Purchases of Equity Securities by the Issuer and Affiliated Purchasers

 

None.

 

Item 3. Defaults upon Senior Securities.

 

Not applicable.

 

Item 4. Mine Safety Disclosures.

 

Not applicable.

 

Item 5. Other Information.

 

None.

 

19

 

 

Item 6. Exhibits.

 

Exhibit       Incorporated by Reference (Unless Otherwise Indicated)
Number   Exhibit Description   Form   File No.   Exhibit   Filing Date
10.11.1   Eyenovia, Inc. 2018 Omnibus Stock Incentive Plan, as amended.   8-K     10.11.1   June 12, 2019
                     
31.1   Certification of the Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002         Filed herewith
                     
31.2   Certification of the Principal Financial and Accounting Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002         Filed herewith
                     
32.1   Certification of the Principal Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002         Filed herewith
                     
32.2   Certification of the Principal Financial and Accounting Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002         Filed herewith
                     
101   Interactive data files pursuant to Rule 405 of Regulation S-T: (i) Balance Sheets as of June 30, 2019 and December 31, 2018; (ii) Statements of Operations for the Three and Six Months Ended June 30, 2019 and 2018; (iii) Statements of Changes in Stockholders’ Equity for the Six Months Ended June 30, 2019 and 2018; (iv) Statements of Cash Flows for the Six Months Ended June 30, 2019 and 2018; and (v) Notes to Condensed Financial Statements         Filed herewith

 

20

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

  EYENOVIA, INC.
     
August 13, 2019 By: /s/ John Gandolfo
    John Gandolfo
    Chief Financial Officer
    (Principal Financial and Accounting Officer)

 

21